Chinese medical company Asclepius Meditec reported on Monday the availability of an environmentally friendly treatment generator AMS-H-03 involving the electrolysis of H2O to produce a mixture of hydrogen and oxygen for inhalation by COVID-19 patients with no side effects.
In a multicentered, open-label clinical trial, titled "Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial", the inhalation of the hydrogen/oxygen mixture prevented the further progression of the disease and, most notably, alleviated the shortness of breath experienced by COVID-19 patients. The results of the research as a treatment for COVID-19 were published in the June 2020 edition of the Journal of Thoracic Disease (JTD).
Asclepius Meditec added that the research and clinical trial was conducted on 44 patients with COVID-19 whose dyspnea could not be ameliorated after regular treatment in 11 hospitals. After three days of continuous use of the hydrogen/oxygen generator, AMS-H-03 , all 44 patients showed significant improvement compared with 46 patients who received the standard regimen of oxygen alone.
According to the company, the hydrogen/oxygen generator AMS-H-03 has received the Class III Medical Device certificate from China's National Medical Products Administration. The AMS-H-03 helps to reduce the mortality rate associated with COVID-19.
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
TuHURA Biosciences acquires Kineta
AbbVie agrees to acquire Capstan Therapeutics
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer